|Application ||WB, E|
|Other Names||Hepatocyte growth factor receptor, HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met, MET|
|Target/Specificity||This monoclonal antibody is generated from mice immunized with a KLH conjugated synthetic peptide corresponding to sequences in Tyr1234/1235 region of human Met and residues both Tyr1234 and Tyr1235 are phosphorylated.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Bi-Phospho-MET/HGFR(Y1234/Y1235) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. Expressed in metaphyseal bone (at protein level) (PubMed:26637977)|
Provided below are standard protocols that you may find useful for product applications.
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene.
MET receptor sequence variants R970C and T992I lack transforming capacity. Tyner JW, et al. Cancer Res, 2010 Aug 1. PMID 20670955. Further evidence for the role of MET in autism susceptibility. Thanseem I, et al. Neurosci Res, 2010 Oct. PMID 20615438. Increased HGF and c-Met in muscle tissues of polymyositis and dermatomyositis patients: beneficial roles of HGF in muscle regeneration. Sugiura T, et al. Clin Immunol, 2010 Sep. PMID 20580899. Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma. Gisterek I, et al. Folia Histochem Cytobiol, 2010 Jan 1. PMID 20529820. MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions. Grabellus F, et al. Tumour Biol, 2010 Jun. PMID 20512480.